IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Kevin P. BAKER, et al. Application Serial No. 10/015,34 Filed: December 12, 2001 For: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NU

Examiner: Nichols, Christopher J.

Art Unit: 1647

Confirmation No: 8886

Attorney's Docket No. 39780-2830 P1C59

Customer No. 35489

EXPRESS MAIL LABEL NO. EL 977 612 471 US

ACIDS ENCODING THE SAME

DATE MAILED: DECEMBER 20, 2004

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

MAIL STOP AMENDMENT

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form Supplemental PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

12/28/2004 WABDELR1-00000020 081641 10015391 1020:00 DA

01 FC:1253

10015391 .2/28/2004 WABDELR1 00000020 081641

	This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):										
		•	han a c	It is being filed ontinued prosector-OR						g date an	id is other
		(2)	It is being filed OR	within	n 3 month	ns of ent	ry of a na	ational s	stage	
		•	3) nerits	It is being filed	before	the mail	l date of	the first	Office A	Action or	the
		,	4)	OR It is being filed uest for continu			_		ice Acti	on after	the filing
	37 C.F.R. $\S1.97(c)$. If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in $\S1.491$ in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under $\S1.113$ or a notice of allowance under $\S1.311$, then:										
		a certific	ation as	s specified in §1	.97(e)	is provid	led belov	w; or			
	\boxtimes	_		as set forth in {other papers file		•			closed,	or includ	ed with
	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:										
	A.	a certific	ation as	s specified in §1	.97(e)	is compl	eted bel	ow; and		•	
	В.	a petition submitted		37 C.F.R. §1.97 vith; and	7(d) red	questing	consider	ration of	this stat	ement is	
	C.	a fee of \$130.00 as set forth in \$1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.									
	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Attorney's Docket No. 39780-2830 P1C59).										
					Respe	ectfully s	ubmitted	d,			
Dated:	Decemb	per 20, 200	04		Ву:	Anna L.	Parry (R	eg. No. :	51 436)	_	
275 Mi Menlo	ddlefield Park, Ca		4025-3	& McAULIFF			Daily (I	95. 110.	J 1,7JU)	·	

.2_

Facsimile: (650) 324-0638

)	Form PTO-	1449	Attorney's Docket No. 39780-2830 P1C59 Application Serial No. 10/015,391						
INFO	RMATI	ON DISCLOS	SURE STATEMENT	Applicant(s) Ke	vin P. BAKER,	et al.				
	(use se	veral sheets	if necessary)	Filing Date: December 12, 2001	Gro 164	up Art Unit: 7				
				U.S. PATENT DOCUMENTS		1000				
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)			
				DREIGN PATENT DOCUMENTS			l	W.S.		
Examiner Initials	Ref. No.	Date	Decument No.	Name	Class	Subclass	Translation YES NO			
			10							
,		-	DEC 2 0 2004 (S)					 		
a de la companya de		E.	f many tincluding	OTHER DOCUMENTS g author, title, date, pertinent pages, e	(c.)		.			
Examiner Initials	Ref. No.	OTHER DOCUMENTS (including author, title, date, pertinent pages, etc.) Title								
	1.	Hanna, J.S., et al., "HER-2/neu Breat Cancer Predictive Testing", Oathology Associates Medical Laboratores - (1999).								
	2.	Hyman, E., et al., "Impact of DNA Amplification on Gene Expression Patterns in Breast Cancer ^{1,2} ", Cancer Research – 62:6240-6245 (2002)								
	3.	Orntoft, T.F., et al., "Genome-wide Study of Gene Copy Numbers, Transcripts, and Protein Levels in Pairs of Non-Invasive and Invasive Human Transitional Cell Carcinomas", <i>Molecular & Cellular Proteomics</i> - 1:37-45 (2002)								
	4.	Pollack, J.R., et al., "Microarray Analysis Reveals a Major Direct Role of DNA Copy Number Alteration in the Transcriptional Program of Human Breast Tumors", <i>PNAS</i> – <u>99(20)</u> :12963-12968 (2002)								
				,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,						
- ,	 	 								
	 	 	11.00 - M M							
	1	1								

EXAMINER:		DATE CONSIDERED:
EVANINED: 1-141-116-14-41	and the continue to the same and the collection and	Some a wish MADED COO. I

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d). SV 2088870 v1